Nasdaq nmra.

Corcept Therapeutics Stock (NASDAQ: CORT) stock price, news, charts, stock research, profile.On Invalid Date, . Neumora Therapeutics (NASDAQ: NMRA) reported Q3 2023 earnings per share (EPS) of -$1.14, up 7.55% year over year. Total Neumora Therapeutics earnings for the quarter were -$53.03 million.In the same quarter last year, Neumora Therapeutics's earnings per share (EPS) was -$1.06.Nov 24, 2023 · A high-level overview of Neumora Therapeutics, Inc. (NMRA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. NMRA | Complete Neumora Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Nasdaq | NMRA U.S.: Nasdaq Neumora Therapeutics Inc. Watch list NEW Set a price target alert After Hours Last Updated: Oct 4, 2023 7:35 p.m. EDT Delayed quote $ 12.27 0.36 3.02% After Hours...

Neumora Therapeutics Inc. (NASDAQ: NMRA) grossed $250.1 million in a September initial public offering that was due in part to a drug pipeline that includes an experimental schizophrenia drug that ...

WATERTOWN, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the initiation of a Phase 1 single ascending dose / multiple ascending dose study evaluating NMRA-266 in healthy adult …Neumora Therapeutics, Inc. Common Stock (NMRA) Option Chain | Nasdaq. Call and put options are quoted in a table called a chain sheet. The chain sheet shows the price, volume and open interest for ...

6 Wall Street analysts have issued 12-month price objectives for Neumora Therapeutics' stock. Their NMRA share price targets range from $18.00 to $26.00. On …Christoph Burgstedt/iStock via Getty Images. Company logo. I started a long position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) last week with a 4.2% portfolio allocation.This recent central ...(NASDAQ:NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will · Neumora ...How much institutional buying is happening at Neumora Therapeutics? Institutional investors have bought a total of 11,743,056 shares in the last 24 months. This purchase volume represents approximately $165.69M in transactions. This page (NASDAQ:NMRA) was last updated on 11/28/2023 by MarketBeat.com Staff.Neumora Therapeutics Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.

Neumora Therapeutics Inc. Common Stock stock performance at a glance. Check Neumora Therapeutics Inc. Common Stock’s past financial performance, like revenue or net …

Corcept Therapeutics Stock (NASDAQ: CORT) stock price, news, charts, stock research, profile.

Successfully completed initial public offering: In September 2023, Neumora completed its initial public offering of its common stock and shares began trading on the Nasdaq Global Select Market under the ticker symbol “NMRA.” Since its inception, Neumora has raised over $850 million to further its mission to confront the ...Neumora Therapeutics, Inc. Common Stock (NMRA) Option Chain | Nasdaq. Call and put options are quoted in a table called a chain sheet. The chain sheet shows the price, volume and open interest for ...NMRA-266 is an investigational positive allosteric modulator of the M4 muscarinic receptor subtype, a clinically validated target for the treatment of schizophrenia. Neumora exclusively licensed ...Watch Nasdaq's Neumora Therapeutics [NMRA] Rings the Nasdaq Opening Bell on Livestream.com.14 Sep 2023 ... Home · News; NMRA. Neumora Therapeutics Inc. - NMRA STOCK NEWS. IMPACT. SENTIMENT. 11/27/2023 07:00 AM. NMRA : Nasdaq.

27 Sep 2023 ... See the latest Neumora Therapeutics Inc stock price (NASDAQ:NMRA), related news, valuation, dividends and more to help you make your ...WATERTOWN, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the initiation of a Phase 1 single ascending dose / multiple ascending dose study evaluating NMRA-266 in healthy adult …Dr. Lenz brings 20 years of neuroscience drug development expertise, with deep experience implementing successful clinical programs to support the development of novel medicines. WATERTOWN, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company …Neumora Therapeutics, Inc. Common Stock (NMRA) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA Get Free Report) traded up 4.6% on Friday . The stock traded as high as $11.21 and last traded at $11.09. 32,521 shares were traded during... Share to Feed. Insider Buying: Neumora Therapeutics, Inc. (NASDAQ:NMRA) Major Shareholder Purchases 30,192 Shares of Stock Ticker Report • …Neumora Therapeutics is a biotech company located in Massachusetts, United States, which is part of the Healthcare sector, and is traded under the ticker NMRA on the NASDAQ exchange. Neumora Therapeutics stock last closed at $11.69 , down 1.35% from the previous day, and has decreased N/A in one year.

Neumora Therapeutics, Inc. Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study. Nov 28. Neumora Therapeutics, Inc. has completed an IPO in the amount of $250.07 million. Sep 16. Earnings and Revenue Growth Forecasts. NasdaqGS:NMRA - Analysts future estimates and past financials data (USD Millions) DateNeumora Therapeutics Inc (NASDAQ: NMRA) gained 15.4% to $14.00 in pre-market trading. Neumora Therapeutics recently initiated a Phase 1 single ascending dose / multiple ascending dose study of ...

Sep 21, 2023 · Shares of Neumora Therapeutics (NMRA 0.41%) were down more than 32% for the week as of Thursday's market close, according to data provided by S&P Global Market Intelligence. Based on analysts offering 12 month price targets for NMRA in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .Canopy Growth Corporation Common Shares. $1.275 -0.065 -4.85%. Neumora Therapeutics, Inc. Common Stock (NMRA) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US ...NVDA. NVIDIA Corporation Common Stock. $439.00 -16.81 -3.69%. Find the latest historical data for Nemaura Medical, Inc. Common Stock (NMRD) at Nasdaq.com. Shares of Neumora Therapeutics (NMRA 0.41%) were down more than 32% for the week as of Thursday's market close, according to data provided by S&P Global Market Intelligence.Current. -$0.75. 1 Month Ago. -$0.75. 3 Months Ago. N/A. Neumora Therapeutics Inc. analyst estimates, including NMRA earnings per share estimates and analyst recommendations.4 hari yang lalu ... Moleculin Biotech (NASDAQ:MBRX) stock is jumping more than 15% without any clear news today. Neumora Therapeutics (NASDAQ:NMRA) shares are up ...CGC. Canopy Growth Corporation Common Shares. $1.275 -0.065 -4.85%. Find the latest SEC Filings data for Neumora Therapeutics, Inc. Common Stock (NMRA) at Nasdaq.com. Created with Sketch. when trading, helping you to optimize your price and have a successful order execution. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4 ...

The Watertown, MA-based Neumora Therapeutics (NASDAQ:NMRA), a Phase 3 biotech developing therapies for brain diseases has priced its initial public offering of 14.71 million shares of its common ...

(NASDAQ:NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will · Neumora ...

Sep 21, 2023 · Investors can buy NMRA even cheaper than Gosebruch did, with shares changing hands as low as $10.01 at last check today -- that's 20.7% under Gosebruch's purchase price. VIDEO: Thursday 9/21 ... Neumora Therapeutics Inc (NASDAQ: NMRA) gained 15.4% to $14.00 in pre-market trading. Neumora Therapeutics recently initiated a Phase 1 single ascending dose / multiple ascending dose study of ...Nov 1, 2023 · Successfully completed initial public offering: In September 2023, Neumora completed its initial public offering of its common stock and shares began trading on the Nasdaq Global Select Market under the ticker symbol “NMRA.” Since its inception, Neumora has raised over $850 million to further its mission to confront the global brain disease ... Nov 22, 2023 · 6 Wall Street analysts have issued 12-month price objectives for Neumora Therapeutics' stock. Their NMRA share price targets range from $18.00 to $26.00. On average, they predict the company's stock price to reach $22.67 in the next year. This suggests a possible upside of 90.3% from the stock's current price. Watch Nasdaq's Neumora Therapeutics [NMRA] Rings the Nasdaq Opening Bell on Livestream.com.Nov 27, 2023 · NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor that Neumora is developing as a treatment for schizophrenia and other neuropsychiatric disorders. Current. -$0.75. 1 Month Ago. -$0.75. 3 Months Ago. N/A. Neumora Therapeutics Inc. analyst estimates, including NMRA earnings per share estimates and analyst recommendations.20 Nov 2023 ... NMRA:NSQNASDAQ. Neumora Therapeutics Inc. Actions. Add to watchlist; Add ... Its other product candidates include NMRA-511, NMRA-266, NMRA-NMDA, ...Minim, Inc. (NASDAQ: MINM) gained 29.3% to $1.19 in pre-market trading after gaining over 13% on Wednesday. ... (NASDAQ: NMRA) gained 15.4% to $14.00 in pre-market trading. Neumora Therapeutics ...On October 10, 2023, Geoff Meacham, an analyst at Bank of America Securities, commenced coverage on Neumora Therapeutics (NASDAQ:NMRA) by Analyst Coverage and Price Targets for Neumora Therapeutics - Best StocksNeumora Therapeutics (NASDAQ:NMRA) shares are up over 15% this morning. 10 Top Losers Vivos Therapeutics (NASDAQ: VVOS ) stock is plummeting nearly 34% after a massive rally yesterday on FDA news .NMRA Neumora Therapeutics, Inc. Stock Price & Overview. Follow 212 followers. $12.250.00 (0.00%)11:37 AM 12/01/23. NASDAQ | $USD | Realtime. Summary · Ratings ...

Nov 1, 2023 · Successfully completed initial public offering: In September 2023, Neumora completed its initial public offering of its common stock and shares began trading on the Nasdaq Global Select Market under the ticker symbol “NMRA.” Since its inception, Neumora has raised over $850 million to further its mission to confront the global brain disease ... Learn more. See all brokers. View live Neumora Therapeutics, Inc. chart to track its stock's price action. Find market predictions, NMRA financials and market news.1.55. EBIT. -130.9. -237.31. Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual ( 10-K) and quarterly ( 10-Q) reports submitted to the Securities and Exchange Commission (SEC). Detailed annual and quarterly income statement for Neumora Therapeutics, Inc. (NMRA). See many years of revenue, expenses and ...Common Stock stock price (NMRA). NASDAQ: NMRA. Buying or selling a stock that's not traded in your local currency? Don't let the currency conversion trip you ...Instagram:https://instagram. mfs utilities fund1776 to 1976 quarter value no mint markbest forex broker in usa mt4usaa animal insurance Neumora Therapeutics, Inc. ( NASDAQ:NMRA – Get Free Report) Director Kristina Burow bought 43,082 shares of the business’s stock in a transaction dated Monday, November 6th. The stock was ... is aetna good medical insuranceohio top financial advisors About Robert Lenz, M.D., Ph.D., executive vice president, head of research and development Dr. Rob Lenz is executive vice president, head of research and development at Neumora. stock.market holidays 2023 The latest price target for Structure Therapeutics ( NASDAQ: GPCR) was reported by JMP Securities on Monday, November 20, 2023. The analyst firm set a price target for 91.00 expecting GPCR to rise ...Oct 10, 2023 · For Neumora Therapeutics Inc (NASDAQ:NMRA), William Blair initiated coverage, by setting the current rating at Outperform. The stock has a 52-week-high of $17.74 and a 52-week-low of $9.90.